Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis

International Immunology

Volumn 18, Issue 12, 2006, Pages 1691-1700

  Sun, Wei ^a   Hong, Jian ^a   Zang, Ying C Q ^a   Liu, Xin ^a   Zhang, Jingwu Z ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXD2; TRANSCRIPTION FACTOR GATA 3; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA FOOTPRINTING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TH1 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33845364048     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl103     Document Type: Article

References (29)

1. Dauphin, F. and MacKenzie, E. T. 1995. Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Pharmacol. Ther. 67:385.
2. Maggi, C. A., Giachetti, A., Dey, R. D. and Said, S. I. 1995. Neuropeptides as regulators of airway function: Vasoactive intestinal peptide and the tachykinins. Physiol. Rev. 75:277.
3. Shuttleworth, C. W. and Keef, K. D. 1995. Roles of peptides in enteric neuromuscular transmission. Regul. Pept. 56:101.
4. Harmar, A. J., Arimura, A., Gozes, I. et al. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50:265.
5. Calvo, J. R., Pozo, D. and Guerrero, J. M. 1996. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv. Neuro-immunol. 6:39.
6. Sreedharan, S. P., Huang, J. X., Cheung, M. C. and Goetzl, E. J. 1995. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc. Natl Acad. Sci. USA 92:2939.
7. Adamou, J. E., Aiyar, N., Van Horn, S. and Elshourbagy, N. A. 1995. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem. Biophys. Res. Commun. 209:385.
8. Sreedharan, S. P., Patel, D. R., Huang, J. X. and Goetzl, E. J. 1993. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193:546.
9. Mackay, M., Fantes, J., Scherer, S. et al. 1996. Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: A possible contributor to the holoprosencephaly 3 phenotype. Genomics 37:345.
10. Usdin, T. B., Bonner, T. I. and Mezey, E. 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662.
11. Lara-Marquez, M., O'Dorisio, M., O'Dorisio, T., Shah, M. and Karacay, B. 2001. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166:2522.
12. Delgado, M. and Ganea, D. 2001. Cutting edge: Is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166:2907.
13. Delgado, M. 2003. VIP: A very important peptide in T helper differentiation. Trends Immunol. 24:221.
14. Delgado, M., Leceta, J., Gomariz, R. P. and Ganea, D. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J. Immunol. 163:3629.
15. Dorsam, G., Voice, J., Kong, Y. and Goetzl, E. J. 2000. Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann. N. Y. Acad. Sci. 921:79.
16. Delgado, M., Abad, C., Martinez, C., Leceta, J. and Gomariz, R. P. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7:563.
17. Feldmann, M., Brennan, F. M. and Maini, R. N. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.
18. Kivisakk, P., Mahad, D. J., Callahan, M. K. et al. 2003. Human cerebrospinal fluid central memory CD4+ T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl Acad. Sci. USA 100:8389.
19. Lassmann, H. and Ransohoff, R. M. 2004. The CD4-Th1 model for multiple sclerosis: A critical [correction of crucial] re-appraisal. Trends Immunol. 25:132.
20. Hohlfeld, R. 1997. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865.
21. Voice, J. K., Grinninger, C., Kong, Y., Bangale, Y., Paul, S. and Goetzl, E. J. 2003. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170:308.
22. Yung, S. L., Dela Cruz, F., Hamren, S. et al. 2003. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J. Biol. Chem. 278:10273.
23. Trinklein, N. D., Aldred, S. J., Saldanha, A. J. and Myers, R. M. 2003. Identification and functional analysis of human transcriptional promoters. Genome Res. 13:308.
24. Sundrud, M. S., Grill, S. M., Ni, D. et al. 2003. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J. Immunol. 171:3542.
25. Johansson, C. C., Dahle, M. K., Blomqvist, S. R. et al. 2003. A winged helix forkhead (FOXD2) tunes sensitivity to cAMP in T lymphocytes through regulation of cAMP-dependent protein kinase RIalpha. J. Biol. Chem. 278:17573.
26. Delgado, M., Pozo, D. and Ganea, D. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56:249.
27. Klein-Hessling, S., Jha, M. K., Santner-Nanan, B. et al. 2003. Protein kinase A regulates GATA-3-dependent activation of IL-5 gene expression in Th2 cells. J. Immunol. 170:2956.
28. Chen, C. H., Zhang, D. H., LaPorte, J. M. and Ray, A. 2000. Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J. Immunol. 165:5597.
29. Lutz, E. M., Shen, S., Mackay, M., West, K. and Harmar, A. J. 1999. Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2. FEBS Lett. 458:197.